Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Equities researchers at Oppenheimer Holdings boosted their Q3 2017 EPS estimates for shares of Vanda Pharmaceuticals in a research report issued on Thursday. Oppenheimer Holdings analyst D. Archila now anticipates that the biopharmaceutical company will earn ($0.08) per share for the quarter, up from their prior forecast of ($0.19). Oppenheimer Holdings currently has a “Buy” rating and a $21.00 target price on the stock. Oppenheimer Holdings also issued estimates for Vanda Pharmaceuticals’ Q4 2017 earnings at ($0.10) EPS, FY2017 earnings at ($0.39) EPS, FY2018 earnings at ($0.28) EPS, FY2019 earnings at $0.11 EPS and FY2020 earnings at $0.54 EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.18. The business had revenue of $42.06 million for the quarter, compared to analyst estimates of $40.31 million. Vanda Pharmaceuticals had a negative return on equity of 7.88% and a negative net margin of 6.54%. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.01 earnings per share.

WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/08/07/q3-2017-eps-estimates-for-vanda-pharmaceuticals-inc-boosted-by-analyst-vnda.html.

A number of other equities research analysts have also issued reports on VNDA. CIBC reaffirmed an “outperform” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, April 12th. Jefferies Group LLC reiterated a “buy” rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a report on Wednesday, April 12th. TheStreet upgraded Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Friday, May 12th. HC Wainwright initiated coverage on Vanda Pharmaceuticals in a report on Friday, May 26th. They set a “buy” rating and a $18.00 price target on the stock. Finally, Zacks Investment Research downgraded Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, June 7th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $21.22.

Shares of Vanda Pharmaceuticals (VNDA) opened at 16.00 on Monday. The firm’s market cap is $715.49 million. Vanda Pharmaceuticals has a 1-year low of $11.58 and a 1-year high of $18.00. The company’s 50 day moving average price is $15.89 and its 200-day moving average price is $14.60.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Asset Management L.P. increased its position in shares of Vanda Pharmaceuticals by 1,544.3% in the first quarter. Point72 Asset Management L.P. now owns 2,484,500 shares of the biopharmaceutical company’s stock worth $34,783,000 after buying an additional 2,333,400 shares during the period. FMR LLC increased its position in shares of Vanda Pharmaceuticals by 60.7% in the first quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock worth $22,416,000 after buying an additional 604,900 shares during the period. Vanguard Group Inc. increased its position in shares of Vanda Pharmaceuticals by 26.4% in the first quarter. Vanguard Group Inc. now owns 2,494,347 shares of the biopharmaceutical company’s stock worth $34,920,000 after buying an additional 521,669 shares during the period. Nexthera Capital LP purchased a new position in shares of Vanda Pharmaceuticals during the first quarter worth approximately $7,171,000. Finally, Renaissance Technologies LLC increased its position in shares of Vanda Pharmaceuticals by 65.3% in the first quarter. Renaissance Technologies LLC now owns 939,250 shares of the biopharmaceutical company’s stock worth $13,150,000 after buying an additional 370,900 shares during the period. Hedge funds and other institutional investors own 91.35% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.